Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of ONO-2910 in Healthy Subjects
NCT04504760Phase 1Completed
- Sponsor
- Ono Pharmaceutical
- Start
- Jul 2020
- Primary completion
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ONO-2910 in diabetic polyneuropathy (DPN) and chemotherapy-induced peripheral neuropathy (CIPN) (4 arms), sponsored by Ono Pharmaceutical. Primary endpoint: Adverse events up to 13 days. Started Jul 2020; status: completed.
02
Drugs
ONO-2910
03
Conditions
diabetic polyneuropathy (DPN)chemotherapy-induced peripheral neuropathy (CIPN)
Beyond the preview
Go deeper on NCT04504760.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04504760.